February 19, 2019
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency

November 13, 2018
Modis Therapeutics Announces PRIME Designation Granted by the European Medicines Agency to MT1621 for the Treatment of TK2 Deficiency

October 29, 2018
Modis Therapeutics Announces Appointment of Matthew R. Patterson to Board of Directors

October 3, 2018
Modis Therapeutics Announces Presentation at International World Muscle Society Congress 2018

October 1, 2018
Modis Therapeutics Announces $30M Series A Financing